2020
DOI: 10.1016/j.ejphar.2020.173584
|View full text |Cite
|
Sign up to set email alerts
|

Targeting DNA and mutant p53 by a naphthalimide derivative, NA20, exhibits selective inhibition in gastric tumorigenesis by blocking mutant p53-EGFR signaling pathway

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2021
2021
2022
2022

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(1 citation statement)
references
References 33 publications
0
1
0
Order By: Relevance
“…The above approaches are only a handful of approaches that are currently being explored to tackle mutp53 cancers. Other approaches target mutp53 downstream signalling pathways including the EGFR signalling pathway with drugs such as NA20 [ 125 ] or cetuximab [ 126 ] use synthetic lethal approaches to find vulnerabilities of mutant p53 cancer cells that can be targeted with drugs [ 127 , 128 ] or target the capacity of mutp53 to form aggregates using compounds such as ReAcp53 [ 129 , 130 ].…”
Section: Strategies That Exploit Mutant P53 Expressionmentioning
confidence: 99%
“…The above approaches are only a handful of approaches that are currently being explored to tackle mutp53 cancers. Other approaches target mutp53 downstream signalling pathways including the EGFR signalling pathway with drugs such as NA20 [ 125 ] or cetuximab [ 126 ] use synthetic lethal approaches to find vulnerabilities of mutant p53 cancer cells that can be targeted with drugs [ 127 , 128 ] or target the capacity of mutp53 to form aggregates using compounds such as ReAcp53 [ 129 , 130 ].…”
Section: Strategies That Exploit Mutant P53 Expressionmentioning
confidence: 99%